email
register here
password
new password
privacy policy
|
imprint | copyright
search
analysis
Meta-analyses-DataBase
2603 publications
< back to search
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.
van der Heijde, Desiree Cheng-Chung Wei, James Dougados, Maxime Mease, Philip Deodhar, Atul Maksymowych, Walter P Van den Bosch, Filip Sieper, Joachim Tomita, Tetsuya Landewe, Robert Zhao, Fangyi Krishnan, Eswar Adams, David H Pangallo, Beth Carlier, Hilde
published in:
Lancet (London, England)
abstract
endpoint
Ixekizumab has (optional: compared with placebo) proved to be better.
general condition better
basics
diagnosis:
ankylosing spondylitis
localization:
not specified
method:
conservative therapy → injection
conservative therapy → injection therapy
conservative therapy → injection therapy
publication details
DOI
10.1016/S0140-6736(18)31946-9
linked to
pubmed
exernal index
30360964
year of publication
2018
journal type
Journal Article
publication type
randomized controlled trial
multicenter
yes
view
prospective
level of evidence
1+
▼
▲